Clinical Scorecard: Analyzing On-Target and Off-Target Binding in Flortaucipir PET: A Voxel-by-Voxel Comparison of P-Tau, Ferric Iron, and MAO-B Histology with Flortaucipir Imaging

At a Glance

Key Highlights

• Flortaucipir PET effectively detects AD-related tau pathology but shows lower retention in non-AD tauopathies.
• Off-target Flortaucipir retention occurs in basal ganglia and other regions, potentially due to ferric iron and MAO-B binding.
• Voxel-wise correlation of PET with histology using CNN methods enables detailed analysis of on-target and off-target binding.

Guideline-Based Recommendations

Diagnosis

• Use Flortaucipir PET for in vivo detection of tau pathology primarily in Alzheimer's disease.
• Interpret Flortaucipir PET signals cautiously in non-AD tauopathies due to potential off-target binding.

Management

• Consider the presence of off-target binding when evaluating Flortaucipir PET results to avoid misinterpretation.
• Incorporate multimodal imaging and histological correlation when possible to improve diagnostic accuracy.

Monitoring & Follow-up

• Utilize Flortaucipir PET to assess neuropathological burden and monitor disease progression in AD.
• Recognize limitations of Flortaucipir PET in tracking tau pathology in non-AD tauopathies.

Risks

• Potential misinterpretation of Flortaucipir PET signals due to off-target binding to ferric iron and MAO-B.
• Confounding effects of astrogliosis-related MAO-B upregulation on PET signal.

Patient & Prescribing Data

Individuals with clinically suspected or confirmed Alzheimer's disease and other tauopathies undergoing PET imaging

Flortaucipir PET provides valuable information on tau pathology but requires careful interpretation to distinguish on-target from off-target signals, influencing diagnostic and therapeutic decisions.

Clinical Best Practices

• Apply voxel-by-voxel correlation methods to improve understanding of Flortaucipir PET signal sources.
• Be aware of regional off-target binding patterns, especially in basal ganglia and related structures.
• Consider ferric iron accumulation and MAO-B expression as contributors to off-target PET signals.
• Use standardized neuropathological assessments alongside imaging for comprehensive evaluation.
• Interpret Flortaucipir PET results within the clinical and pathological context to guide management.

References

• FDA approval of Flortaucipir PET tracer
• Neuropathological guidelines for Alzheimer's disease
• Studies on Flortaucipir off-target binding and iron accumulation